title: Current therapy of the pemphigus group.
abstract: Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.
authors.affiliation: Department of Dermatology, University of Lübeck, Germany. Michael.Kasperkiewicz@uk-sh.de
authors.forename: Michael
authors.initials: M
authors.lastname: Kasperkiewicz
authors.forename: Enno
authors.initials: E
authors.lastname: Schmidt
authors.forename: Detlef
authors.initials: D
authors.lastname: Zillikens
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001781:Blood Component Removal / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D004359:Drug Therapy, Combination; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010392:Pemphigus / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D013205:Staphylococcal Protein A / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D013205:Staphylococcal Protein A; D000069283:Rituximab